Related posts

Markets sink, pre-tariffsMarkets stabilize
Investor Insights

This summary was created by AI, based on 10 opinions in the last 12 months.

Vertex Pharmaceuticals Inc. (VRTX-Q) has garnered mixed reviews from experts following its performance and pipeline developments. The company has made significant strides with its non-addictive painkiller, leading to a 20% increase in shares this year, and its cystic fibrosis portfolio also continues to perform well. However, some analysts express caution due to disappointing updates concerning a key drug and concerns surrounding free cash flow entering 2024. Despite these challenges, the overall sentiment leans positive, with many experts believing in the long-term potential of Vertex's innovative treatments. The stock remains a strong consideration for investors focusing on its growth trajectory in pain management and other therapeutic areas.

Consensus
Positive
Valuation
Fair Value
BUY

A strong performer in this market, not pulling back. Everybody is excited over their pain drug, and other drugs in the pipeline as well. 

PARTIAL SELL

She trimmed it because it's up 20% this year because of the launch of their pain medicine. Tonight's earnings will be fine and their pipeline makes it a good stock long term.

DON'T BUY

They got disappointing news on their wonder drug. Disappointing. Doesn't see upside for the company.

BUY ON WEAKNESS

He likes it for developing non-addictive painkillers with potential FDA approvals ahead. They reported a great quarter a day before the election, but has since pulled back hard that baffles him. Looks like profit-taking in a stock that's jumped 113% since end-2021.

BUY

Their anti-pain drug is not addictive and it works. He's a believer.

BUY

Negative free cash flow to enter 2024, but it's turning positive. Shares are up 21% this year.

HOLD

Even at this all time high don't sell. They're working on non-addictive painkillers

HOLD

It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.

BUY

This drugmaker has a lock on MS and have new shots on pain management and other maladies. Lots going on. Up sharply this month.

BUY

Likes it for its CF franchise.

PARTIAL SELL

Likes it, but she trimmed it because a lot of the good news from its pain medicine is now in the stock.

BUY

PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 04/22, Up 57.9%)Stochchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX has triggered its stop at $350.  To remain disciplined, we recommend covering the position at this time.  This will result in a net investment gain of 44%, when combined with our previous recommendations.

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 04/22, Up 88.8%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VRTX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $330) to $350 at this time.  

BUY

They're in the MS business, so will they expand beyond MS? HE's confident they will and have some hit drugs.

Showing 1 to 15 of 36 entries

Vertex Pharmaceuticals Inc.(VRTX-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 10

Stockchase rating for Vertex Pharmaceuticals Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Vertex Pharmaceuticals Inc.(VRTX-Q) Frequently Asked Questions

What is Vertex Pharmaceuticals Inc. stock symbol?

Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q

Is Vertex Pharmaceuticals Inc. a buy or a sell?

In the last year, 10 stock analysts published opinions about VRTX-Q. 6 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..

Is Vertex Pharmaceuticals Inc. a good investment or a top pick?

Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..

Why is Vertex Pharmaceuticals Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Vertex Pharmaceuticals Inc. worth watching?

10 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.

What is Vertex Pharmaceuticals Inc. stock price?

On 2025-04-01, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $484.74.